The recent results of VERTIS-CV have provided new insights into the individual and class effects of SGLT2 inhibitors, prompting further considerations of the multifactorial effects of these medications. But what made this trial so thought-provoking?

This week, join us for a retrospective review of outcomes trials for SGLT2 inhibitors and a detailed discussion of the VERTIS-CV trial with Dr Chris Cannon, cardiologist at Brigham and Women’s Hospital, professor of medicine at Harvard Medical School and principal investigator for the VERTIS-CV trial.

References

This independent educational activity is supported by an educational grant from Merck Sharp & Dohme Corp. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Merck Sharp & Dohme Corp has had no influence on the content of this education.